Over-expression of CLDN1 has been associated with epithelial–mesenchymal transition, increased invasiveness, and metastatic behavior [66,67], as well as modulation of epithelial barrier permeability, suggesting a role in drug delivery and treatment efficacy—especially in ROS-based cancer therapies. The gene discussed is CLDN1; the disease is cancer.